Compass Therapeutics (NASDAQ:CMPX) Trading Down 5.4% – Here’s Why

Compass Therapeutics, Inc. (NASDAQ:CMPX) dropped 5.4% during mid-day trading on Friday . The stock traded as low as $5.35 and last traded at $5.1580. Approximately 48,950 shares traded hands during trading, a decline of 98% from the average daily volume of 2,246,170 shares. The stock had previously closed at $5.45.

Analysts Set New Price Targets

CMPX has been the topic of several recent analyst reports. Wall Street Zen upgraded Compass Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 16th. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, January 21st. Guggenheim reiterated a “buy” rating and set a $12.00 target price on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.20.

Compass Therapeutics Stock Performance

The firm has a market cap of $931.05 million, a price-to-earnings ratio of -12.02 and a beta of 1.49. The business has a fifty day moving average of $5.76 and a two-hundred day moving average of $5.13.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. On average, equities research analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Creative Planning acquired a new stake in Compass Therapeutics during the 2nd quarter valued at $30,000. Flagship Harbor Advisors LLC acquired a new stake in Compass Therapeutics during the 4th quarter valued at $32,000. Strs Ohio acquired a new stake in Compass Therapeutics during the 1st quarter valued at $34,000. Finally, Apollon Wealth Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.